CardioComm Solutions Appoints New CFO
CardioComm Solutions Appoints New CFO
Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce the appointment of Mr. Robert Caines as Chief Financial Officer ("CFO") of the Company.
安大略省多倫多--（Newsfile Corp.-2024 年 1 月 9 日）- CardioComm 解決方案有限公司 (多倫多證券交易所：EKG) (”心臟通信“或者”公司“）是消費者心臟監測和醫療心電圖（“ECG”）軟件解決方案的全球醫療提供商，很高興地宣佈任命羅伯特·凱恩斯先生爲公司首席財務官（“CFO”）。
Effective January 8, 2024, Mr. Caines assumed the role of CFO, replacing Mr. Etienne Grima who served as interim CFO since August 3, 2023. Mr. Caines will also continue to serve as Chairman of the Board of Directors and Mr. Grima will continue to serve as the Company's Chief Executive Officer.
自2024年1月8日起，凱恩斯先生出任首席財務官，接替自2023年8月3日起擔任臨時首席財務官的艾蒂安·格里瑪先生。凱恩斯先生還將繼續擔任董事會主席，格里瑪先生將繼續擔任公司首席執行官。
The Company also announces that it has issued 250,000 stock options to Etienne Grima, the Company's CEO, in accordance with his employment agreement. The options are exercisable at $0.05 per share for five years from the date of grant and vest immediately. The grant is subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.
該公司還宣佈，已根據公司首席執行官艾蒂安·格里瑪的僱傭協議向其發行了25萬份股票期權。期權自授予之日起五年內可按每股0.05美元的價格行使，並立即歸屬。該補助金受公司股票期權計劃、多倫多證券交易所風險交易所政策以及適用的證券法的約束。
To learn more about CardioComm's products and for further updates please visit the Company's websites at and .
要了解有關CardioComm產品的更多信息以及進一步的更新，請訪問公司的網站和。
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).
關於 CardioComm 解決方案
CardioComm Solutions的專利專有技術用於記錄、查看、分析和存儲心電圖的產品，用於心臟病患者的診斷和管理。產品通過外部分銷網絡和北美銷售團隊的組合在全球範圍內銷售。CardioComm Solutions已獲得ISO 13485和ISO 27001認證，符合HIPAA標準，並持有美國（FDA）和加拿大（加拿大衛生部）的醫療器械許可和銷售許可證。
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
欲了解更多信息，請聯繫：
艾蒂安·格里瑪，首席執行官
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
前瞻性陳述
本新聞稿可能包含與CardioComm Solutions的財務狀況、經營業績和業務以及CardioComm Solutions在這些項目上的某些計劃和目標有關的某些前瞻性陳述和前瞻性信息。此類陳述和信息反映了管理層當前的信念，並基於管理層目前獲得的信息。就其性質而言，前瞻性陳述和前瞻性信息涉及風險和不確定性，因爲它們與事件有關並取決於未來發生的情況，而且有許多因素可能導致實際業績和發展與這些前瞻性陳述和前瞻性信息所表達或暗示的結果和暗示存在重大差異。
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
在評估這些陳述時，讀者不應過分依賴前瞻性陳述和前瞻性信息。除非適用法律（包括但不限於美國國家儀器 51-102）第 5.8 (2) 條，否則公司不承擔任何義務更新本新聞稿中包含的前瞻性陳述和前瞻性信息 (持續披露義務)。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商（該術語在多倫多證券交易所風險交易所的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。